

**PCT**WORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁶: A61L 25/00, A61K 38/36, C07K 14/75	A1	(11) International Publication Number: WO 98/33533 (43) International Publication Date: 6 August 1998 (06.08.98)
(21) International Application Number: PCT/EP98/00502 (22) International Filing Date: 30 January 1998 (30.01.98) (30) Priority Data: 97101569.8 31 January 1997 (31.01.97) EP (34) Countries for which the regional or international application was filed: DE et al. (71) Applicant (for all designated States except US): OMRIX BIOPHARMACEUTICALS S.A. [BE/BE]; 140, avenue Louise, B-1050 Brussels (BE). (72) Inventors; and (75) Inventors/Applicants (for US only): NUR, Israel [IL/IL]; Omri Laboratories Ltd., P.O. Box 619, 76106 Rehovot (IL). BAR, Lilliana [IL/IL]; Omri Laboratories Ltd., P.O. Box 619, 76106 Rehovot (IL). LIEBERMAN, Oded [IL/BE]; Omrix Biopharmaceuticals S.A., 140, avenue Louise, B-1050 Brussels (BE). (74) Agents: MEYERS, Hans-Wilhelm et al.; P.O. Box 10 22 41, D-50462 Cologne (DE).	(81) Designated States: AL, AU, BA, BB, BG, BR, CA, CN, CU, CZ, DE, EE, GE, GW, HU, ID, IL, IS, JP, KP, KR, LC, LK, LR, LT, LV, MG, MK, MN, MX, NO, NZ, PL, RO, SG, SI, SK, SL, TR, TT, UA, US, UZ, VN, YU, ARIPO patent (GH, GM, KE, LS, MW, SD, SZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG). Published <i>With international search report.</i> <i>Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.</i>	
(54) Title: A STABILIZED MIXTURE COMPRISING FIBRINOGEN		
(57) Abstract A stabilized solution of fibrinogen containing samples, in particular a stabilized solution of the biological active component (BAC) which is a solution of proteins derived from blood plasma comprising fibrinogen, tranexamic acid and arginine or lysine or mixtures of arginine and lysine, their pharmaceutically acceptable salts, as well as, optionally, substances forming a buffered solution in aqueous medium.		